Guidance on Identifying Risk Factors for West Nile Virus (WNV) in Potential Living Donors

Ad Hoc Disease Transmission Advisory Committee

Dr. Michael Green, MD, MPH, Chair June 24-25, 2013





OPTN living kidney donor medical evaluation policy implemented in February 2013

- Requires WNV testing for potential kidneys donors from endemic areas
- Confusion in the community regarding specifically who should be tested





Living Donor Committee requested that the DTAC develop guidance to:

Define "endemic areas" for exposure and infection

Discuss testing options





Document Development

The DTAC formed a Work Group to develop this guidance:

- AST Infectious Disease Community of Practice representation
 - Reviewed discussion from 2010 Donor Derived Consensus Conference for Solid Organ Transplantation on WNV
- Reviewed FDA and CDC guidance on this topic for the blood community





Summary of Guidance

The document includes:

- Epidemiology and pathophysiology of WNV
- FDA approved testing options
- DTAC experience on potential transmissions to date
- Risk factors (geographic and seasonal)
- Who and when to test
- What to do with a positive donor test or history of WNV
- Exposure management



Summary of Guidance

Most WNV infections are asymptomatic

- Clinical evaluation will not effectively identify all infection
- Lab testing recommended during periods of human WNV activity where donor lives, works, or travels
- FDA approved screening = NAT
- Initiation of testing based on local human WNV activity informed by local blood bank results
 - May allow centers to test only during periods when human disease is present
 - May reduce false positives and testing costs

Seasonal testing is an alternative, but not as cost effective





 Guidance document will be posted on the OPTN website as a professional resource

 Will be highlighted in UNOS Update and DTAC News e-newsletter





Resolution 2

RESOLVED, that the updated guidance document "Guidance for Identifying Risk Factors for West Nile Virus (WNV) in Potential Living Donors," set forth in Exhibit A to the DTAC's report to the Board, is hereby approved, effective June 25, 2013.

*Page 5 of Board book







Thank you.





Enhancements to the Disease Transmission Reporting Section of the Improving Patient Safety Portal in UNetSM

Ad Hoc Disease Transmission Advisory Committee

Dr. Michael Green, MD, MPH, Chair June 24-25, 2013





Current Reporting Relies on Open Text Field

Little consistency in reporting

 Some sparse, some very lengthy but not including the information DTAC needs to begin review of a potential transmission

Inefficient for members

- Time consuming to draft a narrative
- Greater opportunity for errors or miscommunication

Inefficient for staff

 Can be difficult to glean the details needed by the DTAC without contacting the reporter for more information





isease Transmission event - V		
💽 🗢 🙋 https://portal.unos.o		Bing
Edit View Favorites Tools	Help 🗙 🎭 Convert 🝷 🔂 Select	
avorites 🛛 👍 🏧 Infectious Disea	se Tests C 🔤 Infectious Disease Tests C 🏐 Common Goal Systems Web 脑 Blackboard Lear	rn 🚺 Suggested Sites 👻
Disease Transmission event) 🕆 🖃 🖶 🔻 Page 🔹 Safety 👻 Tools 👻 🕢
efficient avenue for members to	report cases of malignancy and infectious diseases.	SEARCH FOR AN EVENT
vent Information		LEGAL NOTICE
Reporting event for:*	O Donor O Recipient	Reporting a situation or circumstance on this site
Reporting Institution:*		does not imply or provide
Detected by:*	~	any policy, regulatory, or legal protections or
Date occured:*		immunity. It is expected that the information
Medical Condition/Disease:*	Date detected:*	reported will provide data
	MM/DD/YYYY	analysis; enhance patient safety; and improve the
		Add transplantation system.
Description:*		
		Free-form
		text field
ontact Information		
Who at your institution should U		
First name:*	Last name:*	
		🧐 Local intranet 🛛 🖓 👻 🍭 100%
start 🛛 🤌 🐼 📽 🕺 🚺	😼 14 Micros 🔹 🚺 2 Microso 🔹 👩 2 Microso 🔹 🌈 Secure Ent 🥻 Disease Tr	. 🔄 🗐 2013_06_D 🔇 🗢 🔂 💭 🔔 2:47





Proposed Modifications

- Prompts reporter for standard information needed in most potential transmission event reviews
- Incorporates many drop downs and pick lists for diseases and related testing
- Will allow for review of reported data in a more automated fashion within the Improving Patient Safety portal

Modifications expected to streamline reporting process for submitter and staff managing case review!





Reporting event for: *	One of the second se	rdeceased)	C Recipient				
Donor ID:	200045						
Reporting Institution: *	AZOB-Donor Network of Arizona-Independent OPO (Member)						
	,						
Have all of the recipient co		his time ? *	TYES C NO				
Detected by: *	Jane Smith	>					
Infection/Malignancy/Other	Medical Condition (cho	ose all of the a	ppropriate conditions b	eing reported):*			
Infection	Malignancy		Other Medical Co	Indition			
		Enerify Type	-	Date Detected:*			
Infection:* Encephalitis	~	Specify Type Fungal	· ·	06/07/2011	(119911)		
Encophanos					Add		
Infection	Specify Type		Date Detected				
Encephalitis	Fungal		06/07/2011	Delete			
Malignancy:*	Specify		e:*	Date Detected:*			
Basal Cell	×	ABCD	~	06/07/2011	(111111)		
Malignancy	Specify Type		Date Detected		Add		
Basal Cell	ABCD		06/07/2011				
				Date Detected:*			
other Medical Condition:*		Specify Type:*		Date Detected:-			
Hemochromatosis	×	ABCD	~	06/07/2011	(111111)		
					Add		
Other Medical Condition Hemochromatosis	Specify Type ABCD		Date Detected 06/07/2012				
Please attach any relevant	documents, including la	ıb or diagnosti	ic testing results.				
Attachments							
				Browse			
Maximum file size 50mb							
At this time, diagnosis is:	C Confirmed		C Suspected				
	to identify exceptions direct	202	G YES C NO				
Was an assay or other test used If yes, list assay/test type, re							





				Browse
Maximum file size 50mb				
At this time, diagnosis is:	C Confirmed	C 8	Suspected	
			C YES C NO	
/as an assay or other test used to in If yes, list assay/test type, result		upload course		(able)
		upload cor		lable).
Assay/Test Type:	Results:	~	Date:	-
				-
		~		1
~			-	
Was the donor blood sample obtai	ned pre or post transfusion?	C Pre	C Post C Not a	vailable C Unknown
What donor specimens remain for	further testing? (please includ	e type and	amount)	Charles Control of Charles
			1	
Was tissue recovered from this d	onor?			YES ⊂ NO
Was an autopsy completed on th	his donor? (please upload copy	of autopsy	report if available):	THES C NO
Have local/state Public Health a (if appropriate for nationally notifi				rice)?
If yes, please list the name a	ind phone number of your cont	act:		
Name:				
Phone:				
Enter narrative description of thi	s event:* Enter a detail	led descript	ion of the event here.	
ntact information				
Who is the patient safety contact i	at your institution for this event	2		
First name:*		Last name	o:*	
Phone contact (Enter at least on	e): *			
Office:	ext.	Pager/bee	per:	ext
Mobile:	ext.	Other:		- ext.
Email:*				
Other contact info:				
				Submit
the the second state is the second state of th	a till and an a time and a second s	T h	Life and the second second	
to – The screen shot shows is fo	r internation, purposed only	ino actua	TODITION CITA COLOR	

Related Programming

Project Size = Large Effort

- 1570 hours estimated / \$89,219 in cost
- Bulk of time will be IT-related: 1430 hours
 - Split between programming, testing, and education (related to updating help documentation, system notice, etc)

Part 3 of 3 updates to the Improving Patient Safety Portal

- Operations & Safety updates for Patient Safety Situation reporting = very large effort (2580 hours / \$146,848)
- Living Donor Committee updates to Living Donor Adverse Event reporting = medium effort (730 hours / \$43,155)

OPTN



Expected Benefits

For members submitting PDDTE reports

- Easier to know WHAT to report rather than developing a narrative
- Clicking various options MORE TIME EFFICIENT than drafting a narrative

For UNOS staff managing cases

- Information easier to process and prepare for DTAC review
- Receiving the RIGHT information on the front end allows for expedited handling and communication to other recipient centers as needed

Overall, these modifications will allow for a more efficient process all users and enhanced patient safety!





Resolution 9

RESOLVED, that proposed enhancements to the Improving Patient Safety Portal for reporting potential donor-derived disease transmission events be programmed and implemented, effective pending programming and notice to the OPTN membership.

*Page 18 of Board book







Thank you.







OPTN



Factors to Consider During Living Donor Evaluation

- Has human infection with WNV virus been recognized locally this WNV season?
- Has the donor travelled to an area with human WNV activity this WNV season?
- Has the donor ever been diagnosed with WNV fever or WNV neuroinvasive disease?
- Has the donor had an undifferentiated febrile illness within the current WNV season?
- Has the donor had significant mosquito exposure this WNV season?



